Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$286.33
pos +3.20
+1.10%
Today's Range: 283.11 - 286.39 | BIIB Avg Daily Volume: 1,441,600
Last Update: 08/22/17 - 11:09 AM EDT
Volume: 243,912
YTD Performance: 8.35%
Open: $284.13
Previous Close: $283.15
52 Week Range: $223.02 - $338.51
Oustanding Shares: 211,431,746
Market Cap: 59,575,123,070
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 0 0 0 0
Hold 8 7 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.94 1.88 1.80 1.80
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 18.49
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
18.49 16.60 35.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
13.22% -3.02% -9.27%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
EBITDA 4.28B
Revenue 10.13B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $5.61 $5.55 $21.41 $23.11
Number of Analysts 22 22 22 23
High Estimate $6.16 $6.05 $22.31 $25.89
Low Estimate $5.10 $4.85 $20.77 $20.54
Prior Year $5.19 $5.04 $20.22 $21.41
Growth Rate (Year over Year) 8.18% 10.14% 5.87% 7.95%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA

bullishGoldman Sachs Upgrades Biogen to Conviction Buy

Aug 16, 2017 | 9:09 AM EDT
Biogen was added to Goldman Sachs Conviction Buy list and assigned a $338 price target.
RMPIA

bullishBiogen Raised to Buy at Goldman

Jul 26, 2017 | 9:07 AM EDT
Goldman Sachs upgraded Biogen to "Buy" from "Neutral" with a $338 price target.
RMPIA
By

John Reese

 | Jul 25, 2017 | 10:00 AM EDT
These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.
RMPIA
By

Robert Lang

 | Jun 21, 2017 | 10:00 AM EDT
The chart shows this stock has bottomed.
RMPIA
By

Jim Cramer

 | Jun 15, 2017 | 7:31 AM EDT
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
RMPIA
By

Jim Cramer

 | Jun 1, 2017 | 3:55 PM EDT
The market rally broadened out nicely today.
RMPIA
By

Ed Ponsi

 | May 26, 2017 | 10:00 AM EDT
Time to revisit some stocks now that biotech has cooled.
RMPIA
By

Doug Kass

 | Apr 25, 2017 | 3:17 PM EDT
* Biotech (Allergan (AGN) , Celgene (CELG) and Gilead Sciences (GILD) ) * Speculative biotech ( ZIOPHARM Oncology (ZIOP) ,   SAGE Therapeutics (SAGE) , Intrexon (XON) , Valeant Pharmaceuticals (VRX) ,   ACADIA Pharmaceuticals (ACAD) , FibroGen  (FGEN) ). * DuPont (DD) , Netflix (NFLX) , Baidu (BIDU) , Radian (RDN) and Biogen   (BIIB) . * New tech - (T)FANG (TSLA) , (FB) , (AAPL) , (NFLX) , (GOOGL) . * Chipotle Mexican Grill (
RMPIA
By

Jim Cramer

 | Mar 16, 2017 | 12:13 PM EDT
Many want to undo what's been done, but not enough to send the market down.
RMPIA

bearishBiogen downgraded at Leerink

Mar 16, 2017 | 7:13 AM EDT
BIIB was downgraded from Outperform to Market Perform, Leerink Partners said. $300 price target. Spinraza checks suggest a slow start.
I reached out last week to my close friend Ken Shreve, who is a prominent writer for the I...
With the oversold nature (mostly) in markets rallies are going to be sharp and fierce.&nbs...
we will add this here to cheaply protect our downside a bit BOUGHT SPY SEP...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.